Barchart reports on MIRA's experimental pill SKNY-1, an early-stage obesity candidate positioned as an alternative to semaglutide. Results are preliminary.
Recap by typeshit. Full story at Barchart.com.
A Facebook share says Danish teams found certain bacterial strains may change how the gut tells the brain it is full. The work so far is in animal models only.
Bikman calls the results remarkable, but he argues that bigger drops make it more important to know how much of the lost weight is fat and how much is muscle.
Bikman points out that weight usually returns once the drug is stopped, which makes the question of lifelong use a real one.
Avi Roy flags a preprint that pooled 10,052 people from five semaglutide trials and used a blood test to estimate heart age. It has not yet been peer reviewed.
People on weight loss drugs are leaning on alterations and resale shops instead of replacing whole wardrobes as their sizes shift.
Writing in The Pioneer with consultant Neha Bakshi, the Indian policy body's health member calls for a broader approach to treating obesity.
Loading…